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Dendritic cellsMany viruses transmitted via the genital or oral mucosa have the potential to interact with dendritic cell-
speciﬁc intercellular adhesion molecule-3 grabbing non integrin (DC-SIGN) expressed on immature dendritic
cells (iDCs) that lie below the mucosal surface. These cells have been postulated to capture and disseminate
human immunodeﬁciency virus type-1 (HIV-1) to CD4+ lymphocytes, potentially through breaches in the
mucosal lining. We have previously described that BSSL (bile salt-stimulated lipase) in human milk can bind
DC-SIGN and block transfer. Here we demonstrate that seminal plasma has similar DC-SIGN blocking
properties as BSSL in human milk. Using comparative SDS-PAGE and Western blotting combined with mass
spectrometry we identiﬁed mucin 6 as the DC-SIGN binding component in seminal plasma. Additionally, we
demonstrate that puriﬁed mucin 6 binds DC-SIGN and successfully inhibits viral transfer. Mucin 6 in seminal
plasma may therefore interfere with the sexual transmission of HIV-1 and other DC-SIGN co-opting viruses.© 2009 Elsevier Inc. All rights reserved.Introduction
Millions of newly diagnosed infections with human immunodeﬁ-
ciency virus-1 (HIV-1) occur yearly, which could be prevented if a
good vaccine or microbicides were available. Approximately 80% of
new infections with HIV-1 are established through sexual intercourse
(Shattock and Moore, 2003). However risk of transmission is
relatively low with an estimated high number of sexual exposures
required for transmission to occur. Estimates for per-sexual contact
infectivity range from 1:200 for receptive anal intercourse to 1:2000
for receptive vaginal intercourse (O'Brien et al., 1994; Varghese et al.,
2002; Leynaert et al., 1998). Bodily ﬂuids such as semen and cervical
vaginal lavage will undoubtedly contribute to the cellular environ-
ment at the exposed mucosa during sexual intercourse. It is therefore
important to identify possible bodily ﬂuid components affecting initial
interactions of HIV-1 with potential target cells. Such substances, in
addition to known factors, including virus load (Butler et al., 2008),
will likely contribute to host dependent risk of HIV-1 transmission.
During sexual transmission of HIV-1 the virus ﬁrst has to cross the
mucosal epithelial layer of the recipient to gain access to susceptible
cells. Cell types that have been postulated to act as primary targets for).
ll rights reserved.transmitted HIV-1 are CD4+ T-lymphocytes, Langerhans cells (LCs)
and dendritic cells (DCs) (Haase, 2005; de Witte et al., 2007). These
cell types all can be infected with HIV-1 but, in addition, DCs have
been shown, in vitro, to transfer HIV-1 to CD4+ T-lymphocytes
(Geijtenbeek et al., 2000a) without the necessity of infection. DCs are
antigen presenting cells that express several C-type lectins which are
binding receptors for HIV-1. The major C-type lectin on DCs that has
been shown to interact with HIV-1 is DC-SIGN (dendritic cell-speciﬁc
intercellular adhesion molecule-3 grabbing non integrin). DC-SIGN
binds to carbohydrates containing oligo mannose and Lewis sugars
with terminal fucoses of both “self” glycans and glycans of pathogens
(Van Liempt et al., 2004; Van Liempt et al., 2006; Guo et al., 2004; van
Kooyk and Geijtenbeek, 2003). It recognizes a wide range of
pathogens such as Helicobacter pylori, Schistosoma mansoni, Myco-
bacterium tuberculosis and many viruses (e.g. HIV-1, hepatitis C virus,
herpes simplex virus) (Geijtenbeek et al., 2000b; Geijtenbeek and van
Kooyk, 2003; Poumbourios and Drummer, 2007; de Jong et al., 2008;
Jameson et al., 2002; Soilleux et al., 2002; Rappocciolo et al., 2006).
DC-SIGN is used by antigen presenting cells to capture pathogens
or pathogen antigens which are subsequently processed and pre-
sented to T-lymphocytes. Several pathogens transmitted via genital or
oral mucosa interact with DC-SIGN expressed on immature dendritic
cells at the mucosa (Halary et al., 2002; de Jong et al., 2008;
Poumbourios and Drummer, 2007). Although capture of pathogens by
antigen presenting cells via DC-SIGN is necessary for antigen
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infection. Speciﬁcally, immature dendritic cells have been postulated
to capture and disseminate HIV-1 via DC-SIGN following exposure.
This would then, probably, be occurring at damaged epithelia, where
the cell types expressing DC-SIGN come into contact with HIV-1 and
its carrier ﬂuid (Geijtenbeek et al., 2000a). The higher incidence of
HIV-1 transmissions in the context of secondary infections that result
in a damagedmucosal epithelium supports the hypothesis that lesions
in the epithelia provide access for HIV-1 (Celentano et al., 1996;
Corbett et al., 2002; Kaul et al., 2000, 2008).
A number of bodily secretions including human milk, seminal
plasma (SP) and cervical vaginal lavage (CVL) contain components
inﬂuencing the interaction of HIV-1 with CD4+ T-lymphocytes and
DCs (Naarding et al., 2005, 2006; Jendrysik et al., 2005; Sabatte et al.,
2007; Munch et al., 2007). We have previously shown that bile salt-
stimulated lipase (BSSL) in humanmilk is able to bind to DC-SIGN and
block subsequent HIV-1 transfer to CD4+ T-lymphocytes via DCs
(Naarding et al., 2006). We hypothesized that seminal plasma (SP)
contains one or more components that have DC blocking properties
similar to BSSL from human milk. In this study we show that SP,
indeed, has DC blocking properties and we show that the DC-SIGN
binding factor in SP is over 460 kDa. Using different analyses,
including mass spectrometry, we identiﬁed mucin 6 as the DC-SIGN
binding component in SP. Additionally we tested SPs from different
donors and demonstrated that the level of DC-SIGN blocking shows
signiﬁcant differences between SPs from different donors.
Results
Dialyzed seminal plasma is not cytotoxic to Raji DC-SIGN cells
We initially tested the effect of seminal plasma (SP) on transfer of
HIV-1 to CD4+ T-cells by Raji DC-SIGN cells. In this experiment we
observed a high percentage (N90%) of cell death in cell cultures
treated with SP. We hypothesized that the cytotoxicity of SP is caused
by its basic pH and that the cytotoxicity could be alleviated by
dialysis against PBS. To test this hypothesis, we cultured Raji DC-SIGN
cells in the presence of different dilutions of SP or dialyzed SP (DSP).
In Fig. 1 we show a decrease in viability for cells cultured with 32×
diluted SP. More concentrated solutions of SP induced substantial cell
death with over 80% dead cells. These results are in line with
previous observations (O'Connor et al., 1995). In contrast to SP, DSP
was not cytotoxic for the cells at the tested dilutions. No cytotoxicity
of DSP was observed either with immature monocyte derived
dendritic cells (IMDDC) or CD4+ T-cells. Therefore we have used
DSP in our assays in order to exclude interference of cytotoxicity of
SP during our analyses.Fig. 1. Dialyzed seminal plasma is not cytotoxic. Raji DC-SIGN cells were incubated for
2 h with several dilutions of seminal plasma (SP) or dialyzed seminal plasma (DSP). The
cells were then washed with PBS and cultured for 2 days in RPMI. Cell viability was
determined at day 2. Cells cultured in 32 fold or less diluted SP showed increased cell
death. DSP showed no decrease in viability.Seminal plasma contains DC-SIGN binding factors and blocks DC-SIGN
mediated transfer of HIV-1
We tested whether DSP was able to bind DC-SIGN and block DC-
SIGN mediated transfer of HIV-1 to CD4+ T-lymphocytes. DC-SIGN
binding was tested in a DC-SIGN binding ELISA. As DC-SIGN speciﬁc
binding is strictly dependent on Ca2+ ions, incubations in the
presence of Calcium chelators can serve as negative controls. Fig. 2A
shows that DC-SIGN-Fc pre-incubated with TSM only, bound
signiﬁcantly (pb0.0001) stronger to DSP than the EGTA inactivated
DC-SIGN-Fc (negative control), indicating that the DC-SIGN binding of
DSP was speciﬁc.
To test the effect of DSP on DC-SIGN mediated transfer of HIV-1 to
CD4+ T-lymphocytes, we used Raji DC-SIGN cells pre-incubated
without (control) or with different dilutions of DSP. Our results (Fig.
2B) demonstrate that DSP could fully block the transfer of HIV-1 to
CD4+ T-lymphocytes by Raji DC-SIGN cells. Up to 10,000 fold diluted
DSP was still able to block viral transfer by 80%. These results are in
line with the ﬁndings of Sabatte et al. (2007) who described similar
blocking properties for non dialyzed seminal plasma. In addition to
testing the effect of DSP on transfer of HIV-1 by Raji and Raji DC-SIGN
cells, we also tested the effect of DSP in a co-culture of Raji or Raji DC-
SIGN cells with CD4+ T-lymphocytes, HIV-1 and DSP. This system
could be a better reﬂection of the in vivo situation with target cells
exposed to semen and HIV-1 at the same time. Our results show that
DSP also blocks the transfer of HIV-1 under these conditions.
Next, we tested the ability of DSP to block transfer of HIV-1 to
CD4+ T-lymphocytes via IMDDC. We show that 1000 fold diluted DSP
indeedwas able to block transfer of bothNSI-18 (85% blocking, Fig. 2D)
and LAI (68% blocking, Fig. 2E) virus toCD4+T-lymphocytes by IMDDC.
In a co-culture of IMDDC with CD4+ T-lymphocytes, HIV-1 and DSP
we also observed signiﬁcant inhibition of infection (pb0.05) by DSP
(Fig. S1).
DC-SIGN binding and DC blocking properties of DSP derived from
different donors vary
We showed that DSP binds DC-SIGN and blocks both Raji DC-SIGN
and IMDDC mediated transfer of HIV-1 to CD4+ T-lymphocytes. We
next tested the DC-SIGN binding capacity and the ability to block
HIV-1 transfer to CD4+ T-lymphocytes by IMDDCs of DSPs derived
from different donors. We compared DC-SIGN binding of DSP derived
from eight different donors in a DC-SIGN binding ELISA as well as
individual DSP blocking capacity in a HIV-1 transfer assay. The results
of the DC-SIGN binding ELISA demonstrate that DSPs derived from
different donors varied signiﬁcantly (pb0.05) in levels of DC-SIGN
binding (Fig. 3A, left panel). We also determined that the total
protein concentration of the DSP samples (Fig. 3B) did not correlate
with DC-SIGN afﬁnity. To test the HIV-1 transfer blocking capacities of
the same DSPs, we incubated IMDDCs with culture medium (negative
control), DC-SIGN blocking antibody AZN-D1 (positive control) or
1000 fold diluted DSPs derived from each individual. DSPs from the
different donors showed variable blocking capacities of IMDDC
mediated transfer of both NSI-18 and LAI isolates (Fig 3B). Signiﬁcant
differences in blocking capacity were found between donors 2 and 5
and between donors 5 and 8 for both viruses. Additionally, signiﬁcant
differences were found between donors 4 and 7, 5 and 7 and 5 and 9
for NSI-18 and for donors 2 and 4, 2 and 6, 2 and 7, 4 and 8, 5 and 10,
6 and 8 and 7 and 8 for LAI (pb0.05). These results are in agreement
with the variation in DC-SIGN binding in these donors observed in
the DC-SIGN binding ELISA.
Identiﬁcation of DC-SIGN blocking component(s)
After observing that DSP blocks DC-SIGNmediated transfer of HIV-
1 to CD4+ T-lymphocytes, we aimed to identify the component or
Fig. 2. DSP strongly binds DC-SIGN and blocks DC-SIGNmediated transfer of HIV-1 to CD4+ T-lymphocytes. (A) DC-SIGN afﬁnity of DSP (donor 1) was tested in a DC-SIGN ELISA. The
binding signal (measured at 450 nm) for DC-SIGN-Fc pre-incubated with TSM was signiﬁcantly stronger than the binding signal with EGTA inactivated DC-SIGN-Fc (negative
control). (B) The HIV-1 transfer blocking properties of DSP (donor 1) were tested with Raji DC-SIGN cells pre-incubated with RPMI (control (Ctrl)) or different dilutions of DSP.
Transfer was blocked for 80% with 10,000 fold diluted DSP. (C) Additionally, the DC-SIGN blocking properties of DSP (donor 1) were tested in a co-culture of Raji or Raji DC-SIGN cells
with CD4+ T-lymphocytes in the presence of HIV-1mixedwith RPMI or different concentrations of DSP. Both an R5 (NSI-18) and an X4 virus (LAI) were tested. (D and E) The blocking
properties of DSP for HIV-1 transfer to CD4+ T-lymphocytes via IMDDCs was tested with IMDDCs incubated with RPMI (control (Ctrl)), 1000 fold diluted DSP (donor 10) or DC-SIGN
blockingantibodyAZN-D1. Blockingpropertieswere tested for bothaCCR5 (NSI-18,D) andaCXCR4 (LAI, E) using virus.Data fromallﬁgures are shownasmeanvalues of triplicates±standard
error of the means (error bars).
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ﬁrst step was to determine the size range in which the DC-SIGN
blocking component(s) are present. Therefore we separated DSP into
fractions containing components with a molecular weight lower than30 kDa, molecular weight between 30 and 100 kDa and a fractionwith
components larger than 100 kDa. DC-SIGN afﬁnity was measured in
the DC-SIGN binding ELISA and non-fractionated DSP was used as an
input control for the fractionation. Fig. 4 shows the DC-SIGN binding of
Fig. 3. DC-SIGN binding and DC blocking properties of DSP derived from different
donors vary. (A) DC-SIGN binding of DSP was tested in a DC-SIGN ELISA with 1000 fold
diluted DSP. Relative DC-SIGN-Fc binding signal was corrected for non speciﬁc binding
(negative control). The DC-SIGN binding capacity of the strongest binder (donor 8, ⁎)
was set at a 100%. Non speciﬁc DC-SIGN binding was determined for each donor
separately. The panel on the right (white bars) shows the relative protein concentra-
tions of the non diluted tested DSPs. The protein concentration of donor 8 (⁎) with
strongest DC-SIGN binding capacity was set at a 100%. (B and C) Transmission of HIV-1
by IMDDCs to CD4+ T-lymphocytes was determined with FACS. IMDDCs were pre-
incubated with RPMI (positive control), AZN-D1 (negative control) or 1000 fold diluted
DSP from different donors. Results are shown for (B) NSI-18 and (C) LAI isolates.
Fig. 4. The size of the DC-SIGN binding component(s) of DSP is larger than 100 kDa. DSP
was fractionated into fractions with a molecular weight smaller than 30 kDa, 30–
100 kDa and larger than 100 kDa. The fractions were tested for DC-SIGN binding. Non-
fractionated DSP was included as a positive control. DC-SIGN-Fc binding signal
(measured at 450 nm) corrected for non speciﬁc binding (negative control) is shown.
Non speciﬁc DC-SIGN-Fc binding was determined for each sample separately.
Fig. 5. The DC-SIGN binding component in DSP was determined using SDS-PAGE and
Western blot. DSP was separated with a SDS-PAGE gel and blotted on PVDF membrane.
The SDS-PAGE gel (left) was stained with Colloidal Coomassie and the Western blot
(right) was stained with DC-SIGN-Fc and IRdye800 conjugated anti-human-Fc
antibodies. The protein band from the SDS-PAGE that corresponds to the DC-SIGN-Fc
signal on the Western blot was excised from gel and analyzed using MALDI-TOF.
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binding (negative control). The DC-SIGN binding capacity of the
fraction with components larger than 100 kDa had a binding capacity
similar to that of non-fractionated DSP. In contrast, the fraction with
components between 30 kDa and 100 kDa, and the fraction with
components smaller than 30 kDa had no signiﬁcant DC-SIGN afﬁnity.
These results demonstrate that the component or components in DSP
binding to DC-SIGN are larger than 100 kDa.
The DC-SIGN binding component was identiﬁed by separating DSP
using denaturing SDS-PAGE and analyzing the protein positive for DC-
SIGN staining (Western blot) with MALDI-TOF. DSPs from donors 1, 2and 3 were separated using SDS-PAGE and blotted on a PVDF
membrane. The PVDF membrane was stained with DC-SIGN-Fc and
the SDS-PAGE gel with a Colloidal Coomassie stain (Fig. 5). The DC-
SIGN staining showed a single strong signal for a component larger
than 460 kDa (Fig. 5). The protein in the Coomassie stained gel
corresponding to the DC-SIGN signal on the PVDF membrane was
extracted from gel and subsequently analyzed using MALDI-TOF.
Additionally, protein bands negative for DC-SIGN binding were
extracted and analyzed (negative controls). The DC-SIGN binding
protein band was selected for peptide mass ﬁngerprint analysis. The
acquired peptide spectrum from the digested SDS-PAGE band was
searched against non-redundant sequence databases (MSDB and
SwissProt) using the online MASCOT search engine without search
restrictions. In both cases the top score represented Human Mucin 6.
MSDB: Q6W4X9_HUMAN MOWSE Score: 117 with 26 matching
peptides. SwissProt: Muc6_Human MOWSE Score: 99 with 29
Fig. 6. DSP was size fractionated and DC-SIGN binding of the fractions was tested. DSP was fractionated using a superose 6 10/300 GL column with an FPLC (elution of protein was
monitored bymeasuring the optical density at 260 nm (upper right graph). The DC-SIGN afﬁnity was determined for each collected fraction. DC-SIGN-Fc binding signal (measured at
450 nm) corrected for non speciﬁc binding (negative control) is shown (barred graph below). Non speciﬁc DC-SIGN-Fc binding was determined for each fraction separately. The
majority of the DC-SIGN binding was found in the fractions containing molecular weights higher than 700 kDa corresponding to the observation of DC-SIGN binding onWestern blot
(upper left). Fractions 2, 5, 8, 14 and 38 (indicated with asterisk) were digested with trypsin and analyzed with LC/MS/MS.
Fig. 7. Mucin 6 containing fraction of DSP binds DC-SIGN and blocks Raji DC-SIGN
mediated HIV-1 transfer. The HIV-1 transfer blocking properties of fraction 5,
containing mucin 6, and fraction 38, without mucin 6, were tested with Raji or Raji
DC-SIGN cells incubated with RPMI (negative control (Ctrl)), DSP (positive control),
fraction 5 or fraction 38.
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directly, nor when searching the databases with remaining
unmatched peptides). The extracted DC-SIGN negative bands con-
tained human semenogellin 1 and amino peptidase N (human
intestinal CD13).
After identifying the DC-SIGN blocking component in DSP asmucin
6, we aimed to test the DC-SIGN blocking properties of mucin 6 from
DSP in a transfer assay. For this we fractionated DSP using a superose 6
10/300 GL column with an FPLC. Elution of protein from the
fractionated DSP was monitored by measuring the optical density at
280 nm (upper, boxed graph in Fig. 6). The collected fractions were
tested for DC-SIGN binding in a DC-SIGN ELISA (Fig. 6, bar graph
below) and fractions 2, 5, 8, 14, and 38 were digested with trypsin and
analyzed with LC/MS/MS. The vast majority of DC-SIGN binding
activity was found in fractions containing proteins with molecular
weight higher than 700 kDa, which corresponds to the observed
molecular weight of DC-SIGN binding activity found on gel. The strong
DC-SIGN binding fractions 2, 5 and 8 were shown to contain mucin 6,
conﬁrming our previous identiﬁcation of mucin 6 as the DC-SIGN
binding protein in the SDS-PAGE gel. Although themain component in
fraction 14, with intermediate DC-SIGN afﬁnity, was identiﬁed as
clusterin, mucin 6 derived peptides were also detected in this fraction.
A non-DC-SIGN binding fraction (number 38) contained serum
albumin as well as clusterin peptides, demonstrating that clusterin
is not the DC-SIGN binding component. Additionally, in fraction 38 no
mucin 6 derived peptides were found. In conclusion, all fractions
having DC-SIGN binding activity contained mucin 6 peptides.
Fractions without binding afﬁnity did not contain any mucin 6
derived peptides. These results further conﬁrm our initial identiﬁca-
tion of mucin 6, from the SDS-PAGE gel extracted DC-SIGN binding
protein (Fig. 5), as the DC-SIGN blocking component in seminal
plasma.
The capacity of mucin 6 to block DC-SIGN mediated transfer of
HIV-1 to CD4+ T-lymphocytes was tested with fractions derived from
the superose puriﬁcation of DSP. We incubated Raji and Raji DC-SIGN
cells with fraction 5, containingmucin 6, or fraction 38, withoutmucin
6. Raji and Raji DC-SIGN cells incubated with non-fractionated DSP or
RPMI were included as controls. Fig. 7 shows that fraction 5,
containing mucin 6, was able to fully block transfer of HIV-1 by Raji
DC-SIGN cells while fraction 38 without mucin 6 did not inhibit the
transfer. In addition to identifying the glycoprotein responsible for the
DC-SIGN blocking properties of DSP, we characterized which sugars
are providing mucin 6 with its DC-SIGN binding capacity. DC-SIGN is
known to bind to carbohydrates containing oligo mannose or Lewissugars with terminal fucose. We therefore used α1-2,3,6-mannosi-
dase and α1-3,4-fucosidase to deglycosylate SP. The DC-SIGN binding
capacity of deglycosylated SP was then tested for DC-SIGN afﬁnity in a
DC-SIGN binding ELISA. Our results (Fig. S2A) show a non signiﬁcant
decrease in DC-SIGN binding of mannosidase treated SP versus mock
treated SP. Upon fucosidase treatment, however, we observed a
signiﬁcant (pb0.01) decrease of 50% in DC-SIGN binding capacity of
treated SP versus mock treated SP. These results suggest that Lewis
sugars are the main groups providing mucin 6 with its DC-SIGN
binding capacity. We then used an ELISA assay to identify if Lewis
sugars are indeed present in the SP sample tested. Our results show
(Fig. S2B) that Lewis x and Lewis y are indeed present in SP,
conﬁrming previous observations of Chalabi et al. (2002). Taken
together, our results strongly suggest that mucin 6 is the (major)
component in DSP that provides DSP with the capacity to block DC-
SIGN mediated transfer of HIV-1 to CD4+ T-lymphocytes.
Discussion
In this study we demonstrate that, in vitro, a SP component
strongly inhibits DC-SIGNmediated infection of CD4+ T-lymphocytes
in-trans. Furthermore, we showed that the viral transfer blocking
properties of DSPs derived from different donors vary signiﬁcantly.
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DC-SIGN mediated in-trans infection of CD4+ T-lymphocytes was
identiﬁed as mucin 6 (MUC6, gastric mucin-6; mapped to chromo-
some 11p15.5 (Toribara et al., 1993). The basis for this identiﬁcation is
threefold: 1) the protein in the gel at the position of DC-SIGN binding
was unequivocally identiﬁed as mucin 6 by peptide mass ﬁngerprint
analysis, 2) the bulk of the binding activity was in gel ﬁltration
fractions containing proteins over 700 kDa with a strong correlation
between amount of binding activity and the abundance of mucin 6
derived peptides, and 3) mucin 6 is known to express the Lewis y
sugars (Nordman et al., 2002) that can bind to DC-SIGN (and we
showed that removal of DC-SIGN binding Lewis fucoses from SP
greatly decreases the DC-SIGN afﬁnity of SP).
Previously we reported that BSSL in human milk binds DC-SIGN
and blocks DC-SIGNmediated HIV-1 transfer (28). Whenwe observed
that DSP also has DC-SIGN binding and blocking properties, we
hypothesized that the component responsible is BSSL. However, using
SDS-PAGE and Western blotting we noticed that the major DC-SIGN
binding component in DSP is larger than 460 kDa. This implied that
the responsible factor is not BSSL, which is 100–120 kDa in size. Using
MALDI-TOF analysis we subsequently identiﬁed mucin 6 as the major
DC-SIGN binding component of DSP. The protein in the SDS-PAGE gel
corresponding with DC-SIGN binding activity proved to be mucin 6
with a signiﬁcant MOWSE score in our peptide mass ﬁngerprint
analysis while no other proteins could be identiﬁed.
Although we are only looking at very high molecular weight
proteins of over 700 kDa, it could still be possible that less abundant
proteins with very high DC-SIGN binding activity co-migrate with
mucin 6 in a SDS-PAGE gel. However, it is highly unlikely that a
molecule at such low concentrations (MALDI-TOF analysis did not
identify any protein other than mucin 6) would provide this level of
strong inhibitory activity. Ultimately, expression of mucin 6 or
depletion of the molecule from SP will conﬁrm mucin 6 as the
inhibitory factor. But these are complex experiments to perform given
the size of the molecule, the extent/complexity of glycosylation
required for binding to occur and the lack of materials available. We
therefore puriﬁed mucin 6 from DSP with the aid of gel ﬁltration and
analyzed binding afﬁnity and protein content (with tryptic digestion
followed by LC-MS/MS) of the resulting fractions in tandem. Using
this approach we showed that the fractions containing mucin 6 have
strong DC-SIGN binding activity, conﬁrming our previous identiﬁca-
tion of mucin 6 as the (major) DC-SIGN binding component in DSP.
Additionally we showed in a HIV-1 transfer assay with Raji DC-SIGN
cells that the mucin 6 containing fraction is able to block transfer of
HIV-1 via DC-SIGN. Collectively, given the evidence available we are
convinced that the binding and inhibitory activity of SP can be
contributed to mucin 6.
Although the DC-SIGN blocking component in DSP (mucin 6) is not
identical to the DC-SIGN blocking component in human milk (BSSL),
the two factors do share the properties that are likely to provide
effective DC-SIGN binding: both factors are large glycoproteins and
they have the same type of highly O-glycosylated tandem repeats
which form the scaffold for DC-SIGN binding glycans (Landberg et al.,
2000; McKillop et al., 2004;Wang et al., 1995; Andrianifahanana et al.,
2006; Linden et al., 2008). Additionally, both glycoproteins express
Lewis sugars that can bind to DC-SIGN (Van Liempt et al., 2006; Guo et
al., 2004; Nordman et al., 2002; Van Liempt et al., 2004).
Mucin 6 is a member of the mucin family which consists of large
cell membrane associated and secreted glycoproteins (Linden et al.,
2008). These glycoproteins are widely expressed in most epithelia
where the highly glycosylated proteins form a mucus layer that
protects epithelial cells from the exterior environment (Linden et al.,
2008) and proteolysis (Toribara et al., 1993; Jentoft, 1990). Several
members of the mucin family have also been described to be present
in secreted ﬂuids such as saliva, CVL and human milk (Habte et al.,
2006, 2007).We observed that DSPs from different donors have differences in
DC-SIGN afﬁnity and viral transfer blocking capacity. This observation
may, in part, be explained by donor dependent differences in mucin 6
expression levels or differences in post translational modiﬁcations
(Ruvoen-Clouet et al., 2006). Mucin 6 contains a large tandem repeat
domainwhich is highly O-glycosylated and the size of this domain has
been shown to vary considerably between individuals (Rousseau et al.,
2004; Vinall et al., 1998). Interestingly, Nguyen et al. (2006) found
that short mucin 6 alleles are associated with H. pylori infection. It
may therefore be interesting to test if the size of the mucin 6 alleles
also affects DC-SIGN binding of the glycoprotein.
Although our results suggest that the risk of HIV-1 transfer via DC-
SIGN is greatly reduced in the presence of semen, transmission of
seminal HIV-1 particles via DC-SIGN may still occur at low levels. We
observed signiﬁcant differences in DC-SIGN afﬁnity (up to 2.5 fold
differences in ELISA signal intensity) between DSPs derived from the
small number of donors that we tested. Moreover, it is not unlikely
that we will ﬁnd larger differences in DC-SIGN afﬁnity when the
number of screened donors is increased. This indicates that semen of
some individuals will have a reduced protective effect for DC-SIGN
compared to the semen of others. This variation in DC-SIGN afﬁnity of
seminal plasmas from different individuals may translate into
differences between individuals in the risk of transmitting HIV-1 or
other DC-SIGN using pathogens.
In addition to semen and mother milk, also cervical vaginal lavage
(CVL) has the capacity to block DC-SIGNmediated transfer of HIV-1 to
CD4+ T-lymphocytes (Jendrysik et al., 2005). The DC-SIGN blocking
component of CVL has not been identiﬁed yet butmucin 6 is present in
CVL (Andersch-Bjorkman et al., 2007). Based on our observations of
blocking properties of mucin 6, we hypothesize that mucin 6 is
providing CVLwith the described DC-SIGN blocking capacity.With the
observation of DC-SIGN binding and blocking properties of semen,
mother milk and CVL, we see a general theme emerging. Whether
mucin 6 is the blocking compound in CVL or not, in all secretions we
ﬁnd naturally occurring DC-SIGN binding molecules competing with
pathogens for binding to antigen presenting cells (APCs). This could
reﬂect the fact that, while binding to APCs via DC-SIGN can be
important for subsequent antigen presentation, it can also be used by
a pathogen to infect hosts more efﬁciently. This equilibrium could
then be under extra control by the production of competing DC-SIGN
binding molecules. Production of these DC-SIGN binding molecules
may have evolved to protect individuals and their offspring against
continuous challenge by pathogens.
Langerhans cells and dendritic cells are among the ﬁrst cells to be
encountered by HIV-1. Both cell types are preferentially infected by
CCR5 using virus (Reece et al., 1998), the virus type known to establish
initial infection.With our studywe show thatmucin 6 in SP blocks DC-
SIGNmediated transfer of HIV-1 to CD4+ T-cells. This ﬁnding suggests
that, in the presence of semen, HIV-1 capture by DC-SIGN is not likely
to play an important role during the initial establishment of infection
with HIV-1. But DC-SIGN is not required for infection of DCs and thus it
remains possible that DCs are directly infected, leading to the
establishment of a new infection with HIV-1. On the other hand we
cannot exclude that DC-SIGN plays a role when semen is not present
or when DC-SIGN blocking by semen is not 100%. Another remaining
question regards the effect of semen on other C-type lectins.
Langerhans cells express the C-type lectin langerin (de Witte et al.,
2007) which is able to bind HIV-1. In contrast to the sequel upon DC-
SIGN binding, virus captured by langerin is degraded (in the Birbeck
granules) before it can be transmitted to CD4+ T-cells (de Witte et al.,
2006). Langerhans cells can be productively infected when langerin is
blocked and therefore it may be of interest to test whether SP
inﬂuences infection of Langerhans cells. The third cell type that may
serve as initial target for HIV-1 during the establishment of new
infections is the CD4+ T-lymphocyte. Infection levels of CD4+ T-
lymphocytes, in vitro, are low, but the infection levels dramatically
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SIGN expressing cells. Additionally, Munch et al. (2007) have shown
that semen derived amyloid ﬁbrils enhance infection of CD4+ T-
lymphocytes by direct CD4+ cell attachment and, indirect, via DC
transfer. Though one factor in semen enhances infection and another
interferes with DC-SIGN mediated trans-infection, we don't know
which effect will be dominant in vivo. What is clear is that, regardless
of which mechanism is dominant during transmission, the low rate of
HIV-1 transmissions per-sex act suggests that the establishment of
new infections is not very efﬁcient.
With several antiviral properties described for mucins to date,
these glycoproteins are components of the innate immune response
(Habte et al., 2006, 2008; Nguyen et al., 2006). The identiﬁcation of
mucin 6 as a glycoprotein that, like BSSL, is able to prevent viral
hijacking via DC-SIGN provides further insight regarding the innate
immune system. Knowledge gained from understanding the mole-
cular interactions of mucin 6 and BSSL with DC-SIGN can be used in
the development of microbicides that can help prevent HIV-1 or other
pathogen transmissions. The reason being that in the absence of
semen or in situations where the seminal blocking of DC-SIGN is
relatively low, additional DC-SIGN blocking may be beneﬁcial in
reducing the likelihood of transmission. Furthermore, molecules like
mucin 6 and BSSLmay be used to speciﬁcally target therapeutic agents
or vaccine vehicles to DCs via DC-SIGN. Follow up studies are needed
to gain more insight into the molecular structure and glycan
organization of mucin 6 and BSSL, optimal for DC-SIGN binding. For
the development of these molecules as microbicides, additional
research is also required to determine the minimal sizes of these
glycoproteins still providing optimal DC-SIGN binding.
Materials and methods
Cells
The Raji and Raji DC-SIGN cells were obtained and cultured as
previously described (Geijtenbeek et al., 2000a; Naarding et al., 2005,
2006). Peripheral blood mononuclear cells (PBMCs) were isolated
from three buffy coats using ﬁcoll-hypaque density centrifugation and
pooled before freezing. The cells were cultured in RPMI containing 10%
FCS, recombinant IL-2 (100 U/ml), penicillin (100 U/ml) and
streptomycin (100 U/ml) and were activated with phytohemaggluti-
nin (3 μg/ml). At day 3 the PBMCswere enriched for CD4 positive cells
by negative selection using CD8 immunomagnetic beads (Dynal
Biotech). CD4 positive cells were cultured in RPMI containing 10% FCS,
recombinant IL-2 (100 U/ml), penicillin (100 U/ml) and streptomycin
(100 U/ml).
Immature monocyte derived dendritic cells (IMDDCs) were
prepared as previously described (Sallusto and Lanzavecchia, 1994).
Human blood monocytes were isolated from buffy coats by use of a
Ficoll gradient and a subsequent CD14 selection step using a MACS
system (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany). Puriﬁed
monocytes were differentiated into IMDDCs in the presence of
interleukin-4 (IL-4) and granulocyte-macrophage colony-stimulating
factor (500 and 800 U/ml, respectively; Schering-Plough, Brussels,
Belgium) and used on day 6. The phenotype of the IMDDCs was
conﬁrmed by ﬂow cytometry with antibodies against MHC class II
molecules, CD1a, CD11b, CD11c, CD14, ICAM-1, CD83 and CD86. Low
level surface expression of CD83, CD86 and MHC class II was detected
for IMDDCs with high DC-SIGN expression.
Virus
Replication-competent HIV-1 stocks were generated by the
passage of viruses through CD4+ T-lymphocytes as previously
described (Naarding et al., 2005, 2006). Subtype B LAI (X4) and NSI-
18 (R5) were used.Seminal plasma
Semen was centrifuged for 15 min at 14000 rpm. The supernatant
(seminal plasma) was dialyzed in 4 l 0.5× PBS over night at 4 °C using
a 3.5K Slide-A-Lyzer® Dialysis Cassette (Pierce). The buffer was
replaced by fresh 0.5× PBS the next morning and left for another 4 h.
The seminal plasma was collected and centrifuged again for 15 min at
14,000 rpm before storage at −20 °C. Semen samples were donated
by healthy volunteers and used after informed consent. For determin-
ing the protein concentration of DSP, the DSP samples were diluted
1:10 in PBS and the optical density at 280 nm was measured.
Seminal plasma cytotoxicity test
Dilutions of ﬁlter sterile SP or ﬁlter sterile dialyzed SP (DSP) were
made in RPMI supplemented with penicillin (100 U/ml) and
streptomycin (100 U/ml). Raji DC-SIGN cells were incubated for 2 h
after addition of the SP or DSP dilutions. The cells were washed with
PBS and cultured. Cell viability was determined at day 2 using classical
trypan blue staining. The cytotoxicity was determined by calculating
the ratio of non viable versus viable cells.
DC-SIGN mediated transfer of HIV-1 in presence of DSP
DSP dilutions were made in RPMI. Raji or Raji DC-SIGN cells
(5×104 cells/well) were pre-incubated with dilutions of DSP before
addition of 250 TCID50/ml HIV-1 isolate NSI-18. After 60 minute
incubation, the cells were washed and co-cultured with 2×105/well
CD4+ enriched T-lymphocytes. Raji and Raji DC-SIGN cells incubated
with RPMI without DSP before adding virus were used as controls.
Replication of transferred HIV-1 was measured at day 7 using a
standardized capsid-p24 ELISA protocol (Naarding et al., 2006).
Transfer by DCs: Transfer of HIV-1 to CD4+ enriched T-lympho-
cytes by dendritic cells was performed as previously described (van
Montfort et al., 2007). In short, 1×105 immature monocyte derived
dendritic cells (IMDDCs) were incubated for 30 min with 1000 fold
diluted DSP from various donors, or with 20 µg/ml DC-SIGN blocking
antibody at 37 °C. Virus (1.000 TCID50/ml end concentration) was
captured by pre-treated IMDDCs for 2 h at 37 °C. Unbound virus was
removed bywashing IMDDCs three timeswithmedium and cells were
co-cultured with 2.0×105 CD4+ T-lymphocytes in a 96 wells plate.
Mediumwas removed after 48 h and cells were cultured in fresh RPMI,
containing rIL-2 (2 mg/ml) and indinavir (1 μM; NIBSC) for 3 days.
Transmission was determined as the number of infected CD4+ T-
lymphocytes measured by following intracellular CA-p24 expression
by FACS ﬂow cytometry per 1.0×105 CD3+ T-lymphocytes.
Co-culture of DC-SIGN expressing cells and CD4+ T-lymphocytes in
presence of HIV-1 and DSP
DSP dilutions were made in RPMI and 1000 TCID50/ml NSI-18 or
LAI. A mix of Raji or Raji DC-SIGN cells (5×104 cells/well) with CD4+
enriched PBMCs (2×105/well) was plated (150 μl/well). The DSP/
virus mix was then added to the cells (150 μl/well) and incubated at
37 °C. Co-cultures with RPMI but without DSP were used as control.
Replication of transferred HIV-1 was measured at day 3–8 and day 9
using a standardized capsid-p24 ELISA protocol (Naarding et al.,
2006).
Co-culture with DCs: DSP was diluted in RPMI and mixed with
1000 TCID50/ml NSI-18. As controls, a mix of RPMI or 30 μg/ml
mannan with 1000 TCID50/ml NSI-18 was used. A mix of 5×104/well
IMDDCs and 2×105/well CD4+ enriched PBMCs was plated (150 μl/
well). The DSP/virus mix was then added to the cells (150 μl/well)
and incubated at 37 °C. Replication of transferred HIV-1 wasmeasured
at day 7 using a standardized capsid-p24 ELISA protocol (Naarding
et al., 2006).
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Infection was measured using Fluorescent-activated cell sorting
(FACS) analysis (van Montfort et al., 2007). In short, two days after
infection 1mM Indinavir was added to cell cultures. Cells were ﬁxated
4 days after infection in 3.7% formaldehyde and permeabilized in 0.1%
saponin [Riedel-deHaën, S060905] and 1% BSA/50 mMNH4Cl2 in PBS.
Immunostaining was performed with 1:100 anti-human CD3 APC [BD
Pharmingen cat:555335]/1:200 anti P24-FITC [Coulter Clone. Cat
6604665]. The fraction of infected cells was determined using FACS.
DC-SIGN binding ELISA
ELISA plates were coated with SP 1000 fold diluted in 0.2 M
NaHCO3 buffer. For the fractionated DSP a 250 fold dilution was
coated. Plates were incubated with a recombinant human DC-SIGN-Fc
chimera (R&D systems) in TSM buffer (20 mM TRIS, 150 mM NaCl,
1 mM CaCl2 and 2 mM MgCl2) containing 5% BSA as previously
described (Naarding et al., 2005, 2006). Peroxidase labeled anti-
human Fc antibodies (Jackson Immunology) were used to quantify the
bound DC-SIGN-Fc. Non speciﬁc binding of DC-SIGN-Fc was deter-
mined for each individual sample by pre-incubating the calcium
dependent DC-SIGN-Fc for 20minwith 20 mM EGTA (Sigma-Aldrich).
Deglycosylation of seminal plasma
ELISA plates were coated with SP 1000 fold diluted in 0.2 M
NaHCO3 buffer. Coatedwells were treated withα1-2,3,6-mannosidase
(Prozyme) or α1-3,4-fucosidase (Calbiochem) according to the
protocol of the manufacturer. Incubations were performed over
night at 37 °C. After deglycosylation, the wells were washed with
TSM buffer and a DC-SIGN ELISAwas performed to determine the DC-
SIGN binding.
Lewis sugar ELISA
ELISA plates were coated with SP 1000 fold diluted in 0.2 M
NaHCO3 buffer. Coated wells were incubated with mouse anti Lewis b
mAb (T218) (Calbiochem), mouse anti Lewis x (VWR International) or
mouse anti Lewis y mAb (F3) (Calbiochem) 40 fold diluted in TSM
containing 5% BSA or with TSM/BSA only as a negative control. Anti
mouse IgG-HRP antibodies were used to detect bound anti Lewis
antibodies.
Fractionating seminal plasma using centrifugal ﬁlter devices
DSP was fractionated using YM-30 and YM-100 Microcon®
centrifugal ﬁlter devices (Millipore) and as directed in instructions
to users.
SDS-PAGE and Western blot analysis of DSP
DSP was separated using 3–8% NuPage TRIS/acetate gels (Invitro-
gen). Gels were stained with a Colloidal Coomassie stain (Fermentas)
and destained with deionized water. For immunoblotting the gels
were blotted on polyvinylidene diﬂuoride membranes (PVDF-F;
Millipore) and stained with DC-SIGN-Fc (R&D systems, Inc.), and
goat anti-human IgG1 antibody (Jackson Immunoresearch, West
Grove, PA). Visualization was performed using Odyssey infrared
imaging system (LI-COR Biosciences, USA).
Size fractionation of DSP with sepharose
DSP was size fractionated using a superose 6 10/300 GL column
(GE Healthcare) on an Äkta FPLC (GE Healthcare). PBS was used for
column washing and elution.Identiﬁcation of DC-SIGN binding components using mass spectrometry
Protein bands excised from gel were analyzed using Matrix-
assisted laser desorption/ionization-time of ﬂight (MALDI-TOF,
M@LDI, Micromass Wythenshawe, UK) and LC-ESI-MS/MS (QSTAR-
XL, Applied Biosystems/MDS Sciex, Toronto, Canada). In summary,
stained protein bands were cut from the gel. For mass spectrometry
analysis gel slices were S-alkylated with iodoacetamide and vacuum
dried. The in-gel digestion with trypsin (Roche Molecular Biochem-
icals, sequencing grade) and extraction of the peptides upon overnight
incubation were done according to Shevchenko et al. (1996). Dried
peptides were redissolved in 6 μl of a solution containing 1% formic
acid and 60% acetonitrile. The peptide solutions were mixed 1:1 (v/v)
with a solution containing 52 mM α-cyano-4-hydroxycinnamic acid
(Sigma-Aldrich Chemie BV) in 49% ethanol/49% acetonitril/2% TFA
and 1 mM Ammoniumacetate. Prior to dissolving, the α-cyano-4-
hydroxycinnamic acid was washed brieﬂy with acetone. Reﬂectron
MALDI-TOF spectra were acquired on a M@LDI (Micromass Wythen-
shawe, UK). The resulting peptide spectra were used to search the
MSDB databases of the Mascot search engine (http://www.
matrixscience.com). Peptide mixtures and tryptic digests of fractions
of interest (see size fractionation of DSP) were also analyzed. For LC-
ESI-MS/MS analysis, peptide separation was performed using a
nanoscale reversed-phase vented column system ﬁtted onto an
Agilent 1100 series HPLC system, essentially as described in van
Breemen et al. (2008). Samplewas loaded onto a 2 cm×100 μm ID C18
trapping column (Nanoseparations, Bilthoven, The Netherlands) and
trapped peptides were separated with a 63 cm×50 μm ID C18
reversed phase analytical column (Nanoseparations, Bilthoven, The
Netherlands) using a linear gradient of 8–30% solvent B for 95 min
(ﬂow rate of 125 nl/min). The column was interfaced to a QSTAR-XL
mass spectrometer for online electrospray ionization-mass spectro-
metry (ESI-MS) via a liquid junctionwith nebulizer using an uncoated
fused-silica emitter (New Objective, Cambridge, MA, USA) operating
around 4.7 kV (ID, 20 μm, tip ID 10 μm). Survey scans were acquired
from m/z 300–1200 and the three most intense ions were auto-
matically selected for tandem MS. Acquired peptide spectra were
searched against a non-redundant protein sequence database (Swiss-
Prot/TREMBL) using the online MASCOT search engine.
Statistical analysis
Statistical analysis was performed using two tailed unpaired t-
tests. p values b0.05 were considered statistically signiﬁcant.
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